miRNA | Expression in PC tissues | Level in blood | |||||
---|---|---|---|---|---|---|---|
Direction | Ref. | Sample type | Patient groups and sample size | Direction | Normalisation | Ref. | |
Let-7a-5p | Down in PC vs adj. Normal tissues | [45] | Serum | PC (n = 75), BPH (n = 27) | Down in PC | RNA input and miR-16, miR-425 | [52] |
Down in PC vs BPH | [44] | Serum | High grade PC (n = 50), low grade PC (n = 50), BPH (n = 50) | Down in high grade PC vs low grade PC, BPH | RNA input and spike-ins | [12] | |
Serum | Disseminated PC (n = 20), BPH (n = 13) | Up in disseminated PC | Spike-in and miR-320a | [37] | |||
miR-21-5p | Up in PC vs adj. Normal (n = 10) | [55] | Plasma | mCRPC (n = 25, pooled), LPC (n = 25, pooled) | Up in mCRPC | miR-30e | [40] |
Similar in PC and adj. Normal tissues (n = 36) | [56] | Serum | ADPC (n = 20), HRPC (n = 10), LPC (n = 20), BPH (n = 6) | Up in HRPC vs ADPC, LPC | U6 snRNA | [42] | |
Up in PC vs normal tissues | [57] | Plasma | PC (n = 51), HC (n = 20) | Up in PC | RNU1A snRNA | [43] | |
miR-30c-5p | Up in PC vs adj. Normal epithelium (n = 37) | [58] | Serum | High grade PC (n = 50), low grade PC (n = 50), BPH (n = 50) | Down in high grade PC vs low grade, BPH | RNA input and spike-ins | [12] |
Up in PC vs normal tissues | [57] | Plasma | PC (n = 80), BPH (n = 44), HC (n = 54) | Down in PC vs BPH, HC | U6 snRNA | [11] | |
Serum | PC (n = 36), HC (n = 12) | Down in PC | RNA input | [51] | |||
miR-106a-5p | Up in PC vs normal tissues | [57] | Serum | High grade PC (n = 50), low grade PC (n = 50), BPH (n = 50) | Down in high grade PC | RNA input and spike-ins | [12] |
Serum | PC (n = 36), HC (n = 12) | Up in PC | RNA input | [51] | |||
miR-141-3p | Up in mPC, PC vs normal tissues | [53] | Serum | High grade PC (n = 50), low grade PC (n = 50), BPH (n = 50) | Detectable in <50% of patients | RNA input and spike-ins | [12] |
Up in PC vs BPH | [52] | Serum | PC (n = 75), BPH (n = 27) | Up in PC | RNA input and miR-16, miR-425 | [52] | |
Up in BCR after RP vs. no BCR after RP | [59] | Plasma | mCRPC (n = 25, pooled), LPC (n = 25, pooled) | Up in mCRPC | miR-30e | [40] | |
Serum | mCRPC (n = 26), low-risk LPC (n = 28) | Up in mCRCP | U6 snRNA | [53] | |||
Up in PC (n = 36) vs normal tissue (n = 36) | [54] | Plasma EVs | PC (n = 78), HC (n = 28) | Up in PC | Spike-ins | [38] | |
Serum EVs | mPC (n = 47), non-recurrent PC (n = 72) | Up in mPC | |||||
Serum | 71 PC: N1 (n = 48), N0 (n = 23), GS ≥8 (n = 29), GS = 7 (n = 42) | Up in N1 PC vs N0 PC; Up in GS ≥ 8 vs GS = 7 | Spike-ins | [54] | |||
Plasma | mPC (n = 25), LPC (n = 26) | Up in mPC vs LPC; Similar in PC and HC | RNU1A snRNA | [43] | |||
Serum | mPC (n = 25), HC (n = 25) | Up in mPC | Spike-ins | [60] | |||
Serum | PC (n = 54), non-malignant (n = 79) | Up in higher GS; Similar in PC and non-malignant | RNU1–4 and SNORD43 | [61] | |||
miR-200c-3p | Up in PC vs normal tissue | [62] | Plasma | mCRPC (n = 25, pooled), LPC (n = 25, pooled) | Up in mCRPC | miR-30e | [40] |
Serum | mCRPC (n = 25), HC (n = 25) | Up in mCRCP | Spike-ins | [41] | |||
miR-210-3p | Up in PC vs BPH | [44] | Serum | PC (n = 31), BPH (n = 13) | Up in PC | Spike-in and miR-320a | [37] |
Serum | mCRPC (n = 21), HC (n = 20) | Up in mCRCP | Spike-ins | [41] | |||
miR-223-3p | Up in PC vs adj. Normal tissues (n = 10) | [63] | Serum | High grade PC (n = 50), low grade PC (n = 50), BPH (n = 50) | Down in high grade PC vs low grade, BPH | RNA input and spike-ins | [12] |
Up in PC vs normal tissues | [57] | Serum | PC (n = 36), HC (n = 12) | Down in PC | RNA input | [51] | |
miR-375 | Up in mPC, PC vs normal tissues | [53] | Plasma EVs | CRPC (n = 100) | High miRNA level associated with poor OS | RNA input and miR-30a-5p, miR-30e-5p | [39] |
Serum | PC (n = 31), BPH (n = 13) | Up in PC | Spike-in and miR-320a | [37] | |||
Up in PC (n = 36) vs normal tissue (n = 36) | [54] | Plasma | mCRPC (n = 25, pooled), LPC (n = 25, pooled) | Up in mCRPC | miR-30e | [40] | |
Serum | mCRPC (n = 26), low-risk LPC (n = 28) | Up in mCRCP | U6 snRNA | [53] | |||
Serum EVs | mPC after RP (n = 47), non-recurrent PC after RP (n = 72) | Up in mPC | Spike-ins | [38] | |||
Serum | 71 PC: N1 (n = 48), N0 (n = 23), GS ≥8 (n = 29), GS = 7 (n = 42) | Up in N1 PC vs N0 PC; similar in GS ≥ 8 and GS = 7 | Spike-ins | [54] |